The CEO Follows His CFO In, Same Day, Both Washed Out

ISB Research · Favorable · sent to Ultimate members October 1, 2026

Earlier today the finance chief at this epilepsy-drug developer wrote a check. Now the CEO steps in with $1.12 million at $37.38, and he bumped his own stake 151% doing it. That's the kind of commitment that says more than the number alone. Xenon is a neuroscience biotech with its lead candidate, azetukalner, in Phase 3 for epilepsy, so the stock trades on trial readouts and sits near the bottom of its yearly range with RSI at 26. The catch: the broad tape is risk-off and under its short-term trend, which has blunted the washout edge before, so the two-insider signal is the reason to watch, not the chart. A trader who agrees with these two could look at selling a put spread beneath $37.38 to get paid under the price the people running the company just paid.

Ultimate members received this analysis in real time.